Better Pharma ETF: iShares IHE vs. State Street XPH IHE concentrates 23.6% in Eli Lilly and delivers 1.4% yield, while XPH spreads risk across 62 holdings with a lower 0.35% expense ratio.
Alnylam vs. Ionis: Here's the Better Bad-News Buy The sell-offs for both of these beaten-down biotech stocks appear to be overdone.
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? Both face patent cliffs and regulatory headwinds, but their balance sheets and cash generation tell starkly different stories.
2 Growth Stocks to Buy in October Grail and Veeva Systems could be well insulated from near-term headwinds.
Pfizer Stock: Buy, Sell, or Hold? The company is entering what could be a particularly challenging period.
D-Wave Quantum vs. Rigetti Computing: Which Cutting Edge Quantum Stock Is a Better Buy in 2026? D-Wave is growing revenue at nearly 180% while Rigetti trades at a lower valuation, but both burn cash heavily and face unproven commercial roadmaps.
1 Healthcare Stock with Competitive Advantages and 2 We Find Risky Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...
3 of the Best Dividend Stocks to Buy in October 2026 A couple of the stocks on this list pay more than 6% in dividends.
2 Unpopular Stocks That Should Get More Attention and 1 Facing Challenges Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...
Eli Lilly Has Been a Growth Beast, but This Is the Riskiest Part About Its Stock The healthcare stock's elevated valuation bakes in high expectations, leaving little room for error.
Why Pfizer Might Be the Most Underrated Dividend Stock to Buy Right Now Many dividend investors may be overlooking Pfizer's stock, and that could be a costly mistake.
Eli Lilly vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? Eli Lilly is dominating the GLP-1 market with nearly 50% revenue growth and a newly approved oral obesity pill. Pfizer is rebuilding its pipeline with obesity drug ambitions and a committed dividend through its transformation.
Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine Study Vaxcyte stock catapulted Monday after its pneumococcal vaccine proved it's not inferior to shots from Pfizer and Merck.
Better High-Yield Dividend Stock: Pfizer or Novo Nordisk? Novo Nordisk covers its dividend, and Pfizer doesn't, but investors appear increasingly worried about Novo's future.
Here's Exactly Why I'm Not Afraid of Pfizer's 6% Dividend Yield The crowd is looking at the next couple of years. It should be looking five years into the future.
3 Dirt Cheap Dividend Stocks Worth Buying in October There are blazing deals for some of the top healthcare stocks -- companies with proven track records and dividend yields as high as 6%.
3 Income Stocks Under $30 That Yield More Than the 10-Year Treasury Note With the 10-year Treasury yielding around 5.3%, Pfizer, Energy Transfer, and Plains All American offer stocks under $30 with dividend yields between 6% and 7%.
Bristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy? Bristol Myers Squibb isn't a growth stock, but it may offer something to bargain hunters and dividend seekers.
Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP VanEck offers lower costs and double the dividend yield, while Invesco delivered stronger 1-year returns with more balanced holdings.
Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? Novo Nordisk boasts a 33% net margin and fortress balance sheet, while Pfizer trades cheaper but faces major patent cliffs through 2030.
